Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of some unusual options trading on Tuesday. Investors bought 1,612 call options on the stock. This represents an increase of 1,496% compared to the average volume of 101 call options.
In related news, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the sale, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 115,769 shares of company stock worth $1,752,491. Company insiders own 7.63% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter worth approximately $1,472,000. Oppenheimer Asset Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 592.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock worth $338,000 after acquiring an additional 15,295 shares in the last quarter. Granahan Investment Management Inc. MA grew its position in shares of Ironwood Pharmaceuticals by 24.5% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 436,000 shares of the biotechnology company’s stock worth $6,876,000 after acquiring an additional 85,904 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Ironwood Pharmaceuticals by 40.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 143,082 shares of the biotechnology company’s stock worth $2,256,000 after acquiring an additional 41,406 shares in the last quarter. Finally, First Trust Advisors LP grew its position in shares of Ironwood Pharmaceuticals by 20.3% in the 2nd quarter. First Trust Advisors LP now owns 94,732 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 16,018 shares in the last quarter.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.38 on Friday. Ironwood Pharmaceuticals has a 12 month low of $13.43 and a 12 month high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. During the same quarter last year, the firm earned ($0.18) EPS. Ironwood Pharmaceuticals’s quarterly revenue was up 31.3% on a year-over-year basis. analysts anticipate that Ironwood Pharmaceuticals will post -1.11 earnings per share for the current fiscal year.
Several equities research analysts recently commented on the company. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. BidaskClub downgraded Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday. ValuEngine downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Bank of America downgraded Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and dropped their target price for the company from $20.00 to $15.00 in a report on Friday, January 5th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $17.56.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.